Key result
Simvastatin reduces post-injury neointimal thickening via cholesterol-independent smooth muscle cell inhibition.
Why the study?
Simvastatin reduces neointimal proliferation after vascular injury in a cholesterol-independent manner, but the underlying mechanisms require further elucidation.
Prior statin data already establish cholesterol-independent neointimal inhibition; leaves open whether new models add meaningful insight.
We read with interest the study by Chen and associates that showed that simvastatin reduces neointimal proliferation in mice after vascular injury in a cholesterol-independent manner. 1 However, we already documented this finding in vitro and in vivo in a previous article. n fact, it has been documented that simvastatin inhibits in vitro smooth muscle cell proliferation independent of cholesterol. In addition, in vivo experiments have shown that statins potently affect neointimal proliferation in a dose-dependent manner in a reliable model of balloon injury in the rat. ith regard to the potential mechanism of statin on neointimal proliferation, we previously discussed a key role of ras pathway in neointimal proliferation after balloon injury. Recently, we also showed that statins powerfully inhibit ras farnesilation and activation. 4 Therefore, statin-induced Ras-MAPKKs pathway inhibition may play a critical role in the effect of simvastatin on neointimal formation after vascular injury.
No takes yet. Share an insight, caveat, or question.
Curcio et al. (2003) conducted a letter in Neointimal proliferation after vascular injury. Simvastatin was evaluated on Neointimal proliferation. Simvastatin inhibits smooth muscle cell proliferation and reduces neointimal thickening after vascular injury in a cholesterol-independent manner, potentially via the ras pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: